Dr. Reder is a Professor of Medicine at the University of Chicago Medical Center directing the Neurology and Inflammatory Disease Infusion Center where they treat multiple sclerosis, lupus, rheumatoid arthritis, sarcoidosis and Crohn’s disease with cutting edge therapies.
Dr. Reder has coauthored over 120 publications on multiple sclerosis. His primary research interest is in the interaction between the central nervous system (CNS) and the cellular immune system, specifically how drugs used to treat MS modify the brain and immune system. Professor Reder’s research laboratory focuses on the mechanism of action of interferon-beta, the most widely-used treatment for MS. They recently discovered a defect in the lymphocyte interferon signaling pathway in progressive forms of MS possibly explaining why patients with progressive MS do not respond clinically to interferon therapy.
Dr. Reder has participated in the development of multiple new treatments for MS. These include the first biological therapy for MS, interferon-beta, plus other drugs including glatiramer (Copaxone), natalizumab (Tysabri), Rituximab, estriol (the pregnancy hormone), and FTY720/fingolimod, plus drugs for pain in MS such as misoprostol. Current clinical trials include evaluation of IFN-b patients 21 years after the original pivotal trial, the effects of statins on IFN efficacy, and promising new drugs.